NanoString Technologies - Prosigna Breast Cancer Prognostic Gene Signature Assay

Manufactured by  NanoString Technologies
Follow this Equipment

The only PAM50-based breast cancer genomic signature

The Prosigna Breast Cancer Prognostic Gene Signature Assay is a qualitative in vitro diagnostic tool that utilizes gene expression data weighted together with clinical variables to generate a risk category and numerical score to assess a patient’s risk of distant recurrence of disease at 10 years in postmenopausal women with node-negative   
(Stage I or II) or node-positive (Stage II), hormone receptor-positive (HR+) breast cancer. The Prosigna Assay measures gene expression levels of RNA extracted from formalin-fixed paraffin-embedded (FFPE) breast tumor tissue previously diagnosed as invasive breast carcinoma.
Active Questions & AnswersAsk a Question

There are no current Discussions

DNA Sequencing Reagents Service ProvidersView All (3)

Request Support
Features of Prosigna Breast Cancer Prognostic Gene Signature Assay
  • The only PAM50-based breast cancer genomic signature   * The only genomic breast cancer assay that can be run in your pathology lab   * The only test that is FDA 510(k) cleared for FFPE tissue
General Specifications

There are no General Specifications available.

Looking for New or Used Equipment?

Shop on LabX

Shop on Labx.com